Persistent erythema multiforme treated with thalidomide.

Abstract

Erythema multiforme is a common self-limited disorder that predominantly affects younger individuals. It is characterized by typical iris or target lesions on the skin and mucous membranes. Three clinical subgroups of erythema multiforme have been identified: classical erythema multiforme, recurrent erythema multiforme, and persistent erythema multiforme. By definition, persistent erythema multiforme is characterized by the occurrence of continuous typical and atypical lesions without interruption. We report a 15-year-old boy who developed persistent erythema multiforme for 6 months and responded to treatment with thalidomide.

• Authors: Chia-Wei Chen, Tsen-Fang Tsai, Yu-Fu Chen, Chih-Ming Hung
• Journal: American journal of clinical dermatology (Am J Clin Dermatol) Vol. 9 Issue 2 Pg. 123-7 ( 2008) ISSN: 1175-0561 [Print] New Zealand
• PMID: 18284267 (Publication Type: Case Reports, Journal Article)

Chemical References

• Immunosuppressive Agents
• Thalidomide

Topics

• Adolescent
• Erythema Multiforme (drug therapy, pathology)
• Humans
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Male
• Skin (pathology)
• Thalidomide (adverse effects, therapeutic use)